Augustine Lawlor - 31 Jan 2022 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Feb 2022, 20:49:29 UTC
Prior SEC filing
17 Nov 2021
Next SEC filing
09 Aug 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Douglas E. Onsi, as attorney-in-fact for Augustine Lawlor

Key filing fact

Augustine Lawlor filed Form 4 for LEAP THERAPEUTICS, INC. (LPTX) on 02 Feb 2022.

Key facts

  • This page summarizes Augustine Lawlor's Form 4 filing for LEAP THERAPEUTICS, INC. (LPTX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Feb 2022, 20:49.

Change

  • Previous filing in this sequence was filed on 17 Nov 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LPTX transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+225,000
Change %
Price
$0.000000
Shares after
225,000
Date
31 Jan 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
225,000
Exercise price
$0.000000
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.

Footnote F2

The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .